Endonovo Therapeutics (ENDV) 10-Q 19 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 19, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-55453
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	0001528172
Entity Tax Identification Number	45-2552528
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6320 Canoga Avenue
Entity Address, Address Line Two	15th Floor
Entity Address, City or Town	Woodland Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91367
City Area Code	(800)
Local Phone Number	489-4774
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		72,013,761

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 5,732	$ 13,420
Accounts receivable, net of allowance for doubtful accounts of $0	7,092	942
Prepaid expenses and other current assets	49,725	31,825
Total current assets	62,549	46,187
Property, Plant and Equipment, net		1,580
Patents, net	2,074,084	2,559,268
Total assets	2,136,633	2,607,035
Current liabilities
Accounts payable	753,041	700,932
Accrued interest	2,334,302	1,904,136
Deferred compensation	3,970,056	3,384,117
Notes payable, net of discounts of $48,927 and $201,157 as of September 30, 2021, and December 31, 2020	6,639,056	6,491,039
Notes payable – former related party	132,600	143,000
Derivative liability	6,446,149	4,202,597
Total current liabilities	20,275,204	16,825,821
Acquisition payable	79,825	155,000
Total liabilities	20,355,029	16,980,821
COMMITMENTS AND CONTINGENCIES, note 10
Shareholders’ deficit
Preferred value
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 69,193,105 and 24,536,689 shares issued and outstanding as of September 30, 2021, and December 31, 2020	6,920	2,453
Additional paid-in capital	40,615,974	38,963,827
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(58,839,746)	(53,338,522)
Total shareholders’ deficit	(18,218,396)	(14,373,786)
Total liabilities and shareholders’ deficit	2,136,633	2,607,035
Super AA Super Voting Preferred Stock [Member]
Shareholders’ deficit
Preferred value	25	25
Series B Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred value	1	1
Series C Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred value
Series D Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Allowance for doubtful accounts receivable	$ 0	$ 0
Discounts on notes payable current	$ 48,927	$ 201,157
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	69,193,105	24,536,689
Common stock, shares outstanding	69,193,105	24,536,689
Super AA Super Voting Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	25,000	25,000
Preferred stock, shares outstanding	25,000	25,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	600	600
Preferred stock, shares outstanding	600	600
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	8,000	8,000
Preferred stock, shares issued	738	763
Preferred stock, shares outstanding	738	763
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	305	305
Preferred stock, shares outstanding	305	305

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 7,790	$ 39,980	$ 72,789	$ 154,296
Cost of revenue	3,103	760	6,124	18,320
Gross profit	4,687	39,220	66,665	135,976
Operating expenses	696,943	986,019	1,919,418	2,364,213
Loss from operations	(692,256)	(946,799)	(1,852,753)	(2,228,237)
Other income (expense)
Change in fair value of derivative liability	(542,346)	416,370	(2,962,795)	6,016,625
Gain (loss) on settlement of debt	(42,460)	(47,602)	28,536	(564,385)
Other expense		(58,902)		(58,902)
Interest expense, net	(246,612)	(432,108)	(714,212)	(1,530,375)
Other income (expense)	(831,418)	(122,242)	(3,648,471)	3,862,963
Income (Loss) before income taxes	(1,523,674)	(1,069,041)	(5,501,224)	1,634,726
Provision for income taxes
Net Income (loss) income	$ (1,523,674)	$ (1,069,041)	$ (5,501,224)	$ 1,634,726
Basic Income (Loss) per share	$ (0.02)	$ (0.07)	$ (0.10)	$ 0.17
Diluted Income (Loss) per share	$ (0.02)	$ (0.07)	$ (0.10)	$ (0.15)
Weighted average common share outstanding:
Basic	66,291,292	16,137,373	55,303,026	9,621,530
Diluted	66,291,292	16,137,373	55,303,026	23,575,380

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net (Loss) Income	$ (5,501,224)	$ 1,634,726
Adjustments to reconcile net (loss) income to cash used in operating activities:
Depreciation and amortization expense	486,764	488,616
Stock compensation expense	61,453	400,108
Fair value of commitment shares issued with debt	70,971
Fair value of equity issued for services	95,250	13,067
Loss (gain) on extinguishment of debt	(28,536)	564,385
Amortization of note discount and original issue discount	103,659	50,348
Amortization of discount on Series C Preferred stock liability		248
Non-cash interest expense		713,462
Change in fair value of derivative liability	2,962,795	(6,016,625)
Changes in assets and liabilities:
Accounts receivable	(6,150)	21,800
Deposit		(2,500)
Prepaid expenses and other current assets	(17,900)	18,320
Account payable	52,109	82,006
Accrued interest	539,582	766,319
Deferred compensation	585,939	716,986
Net cash used in operating activities	(595,288)	(548,734)
Financing activities:
Proceeds from the issuance of notes payable	475,000	401,424
Repayments to former related-party of notes payable	(10,400)	(19,000)
Repayments of convertible debt in cash	(3,000)
Proceeds from issuance of common stock and units	126,000	100,000
Proceeds from issuance of preferred stock		50,000
Net cash provided by financing activities	587,600	532,424
Net decrease in cash	(7,688)	(16,310)
Cash, beginning of year	13,420	18,893
Cash, end of period	5,732	2,583
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	458,335	1,357,573
Issuance of common stock to settle debt	127,522
Conversion of Preferred C Stock to common stock	33,333	1,400,934
Issuance of common stock to Preferred C Stock inducement		8,152
Exchange of note and accrued interest to new convertible note		$ 316,494

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)	Series AA Preferred Stock [Member]Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Subscription Receivable [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 25	$ 1			$ 118	$ 32,432,392	$ (1,570)	$ (52,934,786)	$ (20,503,820)
Beginning balance, shares at Dec. 31, 2019	25,000	600	255		1,189,204
Reclassification Preferred Series C						2,418,269			2,418,269
Reclassification Preferred Series C, shares				1,814
Shares issued for Preferred Series D						50,000			50,000
Shares issued for Preferred Series D, shares			50
Shares issued for conversion of notes payable and accrued interest					$ 439	2,545,275			2,545,714
Shares issued for conversion of notes payable and accrued interest, shares					4,388,291
Shares issued for conversion of Preferred Series C to Common share					$ 164	(164)
Shares issued for conversion of Preferred Series C to common share, shares				(936)	1,636,166
Valuation of stock options issued for services						9,567			9,567
Net income (loss)								4,338,418	4,338,418
Ending balance, value at Mar. 31, 2020	$ 25	$ 1			$ 721	37,455,339	(1,570)	(48,596,368)	(11,141,852)
Ending balance, shares at Mar. 31, 2020	25,000	600	305	878	7,213,661
Beginning balance, value at Dec. 31, 2019	$ 25	$ 1			$ 118	32,432,392	(1,570)	(52,934,786)	(20,503,820)
Beginning balance, shares at Dec. 31, 2019	25,000	600	255		1,189,204
Common stock issued for services									$ 39,500
Common stock issued for services, shares									385,000
Net income (loss)									$ 1,634,726
Ending balance, value at Sep. 30, 2020	$ 25	$ 1			$ 1,731	38,545,743	(1,570)	(51,308,212)	(12,762,282)
Ending balance, shares at Sep. 30, 2020	25,000	600	305	763	17,303,952
Beginning balance, value at Mar. 31, 2020	$ 25	$ 1			$ 721	37,455,339	(1,570)	(48,596,368)	(11,141,852)
Beginning balance, shares at Mar. 31, 2020	25,000	600	305	878	7,213,661
Shares issued for conversion of notes payable and accrued interest					$ 335	475,627			475,962
Shares issued for conversion of notes payable and accrued interest, shares					3,353,044
Shares issued for conversion of Preferred Series C to Common share					$ 99	27			126
Shares issued for conversion of Preferred Series C to common share, shares				(105)	985,322
Restricted shares issued as inducement to Series C					$ 6	8,146		(8,152)
Restricted shares issued as inducement to Series C, shares					58,428
Common stock issued for services					$ 3	3,497			3,500
Common stock issued for services, shares					25,000
Commitment shares					$ 39	55,501			55,540
Commitment shares, shares					385,963
Common Shares issued for debt settlement					$ 41	58,814			58,855
Common Shares issued for debt, shares					409,000
Net income (loss)								(1,634,651)	(1,634,651)
Ending balance, value at Jun. 30, 2020	$ 25	$ 1			$ 1,244	38,056,951	(1,570)	(50,239,171)	(12,182,520)
Ending balance, shares at Jun. 30, 2020	25,000	600	305	773	12,430,418
Shares issued for conversion of notes payable and accrued interest					$ 76	70,334			70,410
Shares issued for conversion of notes payable and accrued interest, shares					759,669
Shares issued for conversion of Preferred Series C to Common share					$ 13	(13)
Shares issued for conversion of Preferred Series C to common share, shares				(10)	133,334
Valuation of stock options issued for services						20,490			20,490
Common stock issued for services					$ 36	35,964			36,000
Common stock issued for services, shares					360,000
Commitment shares					$ 39	42,340			42,379
Commitment shares, shares					385,963
Shares issued for exchange of stock options					$ 150	164,850			165,000
Shares issued for exchange of stock options, shares					1,500,000
Shares issued as inducement to note holder					$ 50	54,950			55,000
Shares issued as inducement to note holder, shares					500,000
Stock-based compensation					$ 123	99,877			100,000
Common stock issued for cash, shares					1,234,568
Net income (loss)								(1,069,041)	(1,069,041)
Ending balance, value at Sep. 30, 2020	$ 25	$ 1			$ 1,731	38,545,743	(1,570)	(51,308,212)	(12,762,282)
Ending balance, shares at Sep. 30, 2020	25,000	600	305	763	17,303,952
Beginning balance, value at Dec. 31, 2020	$ 25	$ 1			$ 2,453	38,963,827	(1,570)	(53,338,522)	(14,373,786)
Beginning balance, shares at Dec. 31, 2020	25,000	600	305	763	24,536,689
Shares issued for conversion of notes payable and accrued interest					$ 1,769	831,429			833,198
Shares issued for conversion of notes payable and accrued interest, shares					17,686,548
Valuation of stock options issued for services						20,471			20,471
Stock-based compensation					$ 700	125,300			126,000
Common stock issued for cash, shares					7,000,000
Shares issued as commitment to note holders					$ 230	101,652			101,882
Shares issued as commitment to note holders, shares					2,300,334
Net income (loss)								(2,680,881)	(2,680,881)
Ending balance, value at Mar. 31, 2021	$ 25	$ 1			$ 5,152	40,042,679	(1,570)	(56,019,403)	(15,973,116)
Ending balance, shares at Mar. 31, 2021	25,000	600	305	763	51,523,571
Beginning balance, value at Dec. 31, 2020	$ 25	$ 1			$ 2,453	38,963,827	(1,570)	(53,338,522)	$ (14,373,786)
Beginning balance, shares at Dec. 31, 2020	25,000	600	305	763	24,536,689
Common stock issued for cash, shares									2,500,000
Net income (loss)									$ (5,501,224)
Ending balance, value at Sep. 30, 2021	$ 25	$ 1			$ 6,920	40,615,974	(1,570)	(58,839,746)	(18,218,396)
Ending balance, shares at Sep. 30, 2021	25,000	600	305	738	69,193,105
Beginning balance, value at Mar. 31, 2021	$ 25	$ 1			$ 5,152	40,042,679	(1,570)	(56,019,403)	(15,973,116)
Beginning balance, shares at Mar. 31, 2021	25,000	600	305	763	51,523,571
Shares issued for conversion of notes payable and accrued interest					$ 381	116,165			116,546
Shares issued for conversion of notes payable and accrued interest, shares					3,804,103
Shares issued for conversion of Preferred Series C to Common share					$ 111	(111)
Shares issued for conversion of Preferred Series C to common share, shares				(25)	1,111,111
Valuation of stock options issued for services						20,491			20,491
Common Shares issued for debt settlement					$ 152	57,576			57,728
Common Shares issued for debt, shares					1,515,152
Shares issued as commitment to note holders					$ 20	6,280			6,300
Shares issued as commitment to note holders, shares					200,000
Shares issued as settlement of debt with former related party					$ 251	84,446			84,697
Shares issued as settlement of debt with former related party, shares					2,505,834
Net income (loss)								(1,296,669)	(1,296,669)
Ending balance, value at Jun. 30, 2021	$ 25	$ 1			$ 6,067	40,327,526	(1,570)	(57,316,072)	(16,984,023)
Ending balance, shares at Jun. 30, 2021	25,000	600	305	738	60,659,771
Shares issued for conversion of notes payable and accrued interest					$ 420	126,040			126,460
Shares issued for conversion of notes payable and accrued interest, shares					4,200,000
Stock-based compensation						20,491			20,491
Common shares issued pursuant to consulting agreement					$ 250	95,000			95,250
Common shares issued pursuant to consulting agreement, shares					2,500,000
Common shares issued as commitment to note holders					$ 183	46,917			47,100
Common shares issued as commitment to note holders, shares					1,833,334
Net income (loss)								(1,523,674)	(1,523,674)
Ending balance, value at Sep. 30, 2021	$ 25	$ 1			$ 6,920	$ 40,615,974	$ (1,570)	$ (58,839,746)	$ (18,218,396)
Ending balance, shares at Sep. 30, 2021	25,000	600	305	738	69,193,105

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV). The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders). The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke. Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical ® ® bioelectricity

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of significant accounting policies	Note 2 – Summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2021, and 2020, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2021. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. As of September 30, 2021, the Company had cash of approximately $ 6,000 20.2 0.6 58.8 During the nine months ended September 30, 2021, the Company has raised approximately $ 0.6 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential, future, license agreements, has raised capital through the sale of its common stock, and the issuance of convertible promissory notes. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the nine months ended September 30, 2021, include stock options, warrants, and notes payable. The Company has 3,013,730 26,115 96,533 56,914 The components of basic and diluted earnings per share for the nine months ended September 30, 2021, and 2020 were as follows: Schedule of Earnings (Loss) Per Share 2021 2020 Nine months ended September 30, 2021 2020 Numerator: Net income (loss) attributable to common shareholders $ (5,501,224 ) $ 1,634,726 Effect of dilutive securities Convertible notes - (5,063,936 ) Net loss for diluted earnings per share $ (5,501,224 ) $ (3,429,210 ) Denominator: Weighted-average number of common shares outstanding during the period 55,303,026 9,621,530 Dilutive effect of convertible notes payable - 13,953,850 Common stock and common stock equivalents used for diluted earnings per share 55,303,026 23,575,380 Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 as of September 30, 2021, and December 31, 2020. Account receivables are written off when all collection attempts have failed. Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development 0 and $ 3,283 for the nine months ended September 30, 2021, and 2020, respectively, and are included in operating expenses in the condensed consolidated statements of operations. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) Recently Issued Accounting Pronouncements Accounting Principles Not Yet Adopted In May 2021, the FASB issued ASU 2021-04 ASU 2021-04 Newly Adopted Accounting Principles In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s condensed consolidated results of operations, financial position, and cash flows. In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The objective of this standard update is to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. This ASU also attempts to improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard update is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2021, and the impact of adoption was not material to the Company’s financial position, results of operations and cash flows. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued)

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 - Revenue Recognition Contracts with Customers The Company adopted ASC 606, Revenue from Contracts with Customers . The Company routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. Sources of Revenue The Company has identified the following revenues by revenue source: 1. Medical care providers As of September 30, 2021, and 2020, the sources of revenue were as follows: Schedule of Source of Revenue Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Direct sales- Medical care providers, gross $ 7,790 $ 39,980 $ 72,789 $ 154,296 Total sources of revenue $ 7,790 $ 39,980 $ 72,789 $ 154,296 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 4 – Property, Plant and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2021, and December 31, 2020: Summary of Property, Plant and Equipment September 30, December 31, Autos $ 64,458 $ 64,458 Medical equipment 13,969 13,969 Other equipment 11,367 11,367 Property, Plant and Equipment, gross 89,794 89,794 Less accumulated depreciation 89,794 88,214 Property, Plant and Equipment, net $ - $ 1,580 Depreciation expense for the nine months ended September 30, 2021, and 2020 was $ 1,580 3,432 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued)

Patents

Patents	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 5 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $ 4,500,000 2024 Schedule of Patents September 30, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,425,916 1,940,732 Patents, net $ 2,074,084 $ 2,559,268 Amortization expense associated with patents was $ 485,184 The estimated future amortization expense related to patents as of September 30, 2021, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending September 30, Amount 2021 $ 646,910 2022 646,910 2023 646,910 2024 133,354 Total $ 2,074,084

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 6- Notes Payable Notes Payable During the nine months ended September 30, 2021, the Company issued five (5) fixed rate promissory notes totaling $ 475,000 475,000 original terms of twelve months and interest rates of 15 During the nine months ended September 30, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 Debt-Modifications and Extinguishments 58,407 During the nine months ended September 30, 2021, the Company settled one of its promissory notes by issuing 1,515,152 15 128,000 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) During the nine months ended September 30, 2021, the Company paid $ 3,000 During the nine months ended September 30, 2021, the Company converted $ 358,443 99,892 25,690,651 The gross amount of all convertible notes with variable conversion rates outstanding as of September 30, 2021 is $ 4,770,926 , of which $ 2,660,476 are past maturity. Notes payable to a former related party in the aggregate amount of $ 132,600 were outstanding at September 30, 2021, which are past maturity date. The notes bear interest between 10 % and 12 % per annum. During the nine months ended September 30, 2021, the Company paid $ 10,400 in principal to this former related party. As of September 30, 2021, fixed rate notes payable outstanding totaled $ 1,292,154 85,154 Schedule of Notes Payable September 30, December 31, 2020 Notes payable at beginning of period $ 6,835,196 $ 6,874,795 Notes payable issued 475,000 1,364,611 Liquidated damages - 452,095 Note modification - 25,190 Loan fees added to note payable - 120,389 Repayments of notes payable in cash (13,400 ) (22,000 ) Settlements on note payable (117,770 ) (697,253 ) Less amounts converted to stock (358,443 ) (1,282,631 ) Notes payable at end of period 6,820,583 6,835,196 Less debt discount (48,927 ) (201,157 ) $ 6,771,656 $ 6,634,039 Notes payable issued to a former related party $ 132,600 $ 143,000 Notes payable issued to non-related parties $ 6,639,056 $ 6,491,039 The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Related party Non-related parties Total Past due $ 132,600 $ 3,370,533 $ 3,503,133 September 30, 2022 - 3,317,450 3,317,450 $ 132,600 $ 6,687,983 $ 6,820,583 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued)

Shareholders_ Deficit

Shareholders’ Deficit	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Shareholders’ Deficit	Note 7 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Number of Shares Outstanding Shares Authorized at September 30, 2021 Par Value Liquidation Value Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million ( 1,000,000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. 25,000 Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 75 three-year 150 100 600 Series C Convertible Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 20.00 1,000 the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $ 1,000 During the nine months ended September 30, 2021, and 2020, the Company converted 25 1,051 1,111,111 2,754,822 738 Series D Convertible Preferred Stock On November 11, 2019, the Company filed a certificate of designation for 20,000 0.01 The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $ 1,000 305 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) Common Stock Equity Purchase Line Agreement On May 18, 2020, the Company and Cavalry Fund I LP (the “investor”) entered into an Equity Line Purchase Agreement (“ELPA”) pursuant to which the investor committed to purchase, subject to certain restrictions and conditions, up to $ 10,000,000 The Company agreed to issue shares of its common stock (the “commitment shares”) to the investor having a market value of 5% of the commitment ($ 500,000 3,859,630 385,963 3,000,000 The ELPA provides that at any time after the effective date of the registration statement and provided the closing sale price of the common shares on the OTCQB is not below $ 0.01 300,000 400,000 0.25 500,000 0.40 Under the ELPA the Company has the right to submit a regular purchase notice to the investor as often as every business day. The payment for the shares covered by each put notice will generally occur on the day following the put notice. The ELPA contains provisions which allow for the Company to make additional puts beyond the regular purchase amount at greater discounts to the market price of the common stock as forth in the ELPA. The ELPA requires the Company to apply at least 50 Activity during the nine months ended September 30, 2021 During the nine months ended September 30, 2021, the Company issued 25,690,651 458,335 During the nine months ended September 30, 2021, the Company issued 4,333,668 During the nine months ended September 30, 2021, the Company issued 7,000,000 126,000 During the nine months ended September 30, 2021, the Company issued 1,111,111 33,333 During the nine months ended September 30, 2021, the Company issued 4,020,986 142,424 2,505,834 84,697 During the nine months ended September 30, 2021, the Company issued 2,500,000 Activity during the nine months ended September 30, 2020 During the nine months ended September 30, 2020, pursuant to the execution of the ELPA, the Company issued 771,926 97,918 During the nine months ended September 30, 2020, the Company issued 8,501,004 1,381,650 During the nine months ended September 30, 2020, the Company issued 2,754,822 1,400,934 During the nine months ended September 30, 2020, the Company issued 58,428 8,152 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) During the nine months ended September 30, 2020, the Company issued 385,000 39,500 During the nine months ended September 30, 2020, the Company issued 409,000 58,855 283,000 525,000 151,496 Debt-Modifications and Extinguishments During the nine months ended September 30, 2020, the Company issued 1,234,568 100,000 During the nine months ended September 30, 2020, the Company issued 1,500,000 165,000 34,690 During the nine months ended September 30, 2020, the Company modified the terms of its promissory note with one investor, which extended the maturity date of its promissory note and the issuance of 500,000 restricted stock with a fair value of $ 55,000 . The recording of this transaction resulted in a loss on debt extinguishment of $ 55,000 per ASC 470-60 Troubled Debt Restructurings. Stock Options The balance of all stock options outstanding as of September 30, 2021, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2021 3,014,080 $ 0.37 1.67 - Granted - $ - - - Cancelled (350 ) $ 47.00 - - Exercised - $ - - - Outstanding at September 30, 2021 3,013,730 $ 0.37 0.92 $ - Exercisable at September 30, 2021 1,263,730 $ 0.67 0.95 $ - Share-based compensation expense for the nine months ended September 30, 2021, totaled approximately $ 61,000 The total unrecognized compensation expense amounts to approximately $ 137,000 On June 11, 2020, the Board of Directors approved the issuance of 74,668,000 Warrants A summary of the status of the warrants granted under these agreements at September 30, 2021, and changes during the nine months then ended is presented below: Schedule of Warrants Outstanding Outstanding Warrants Weighted Average Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2021 39,295 $ 200.72 0.93 Granted - $ - - Cancelled (13,180 ) $ 449.15 - Exercised - $ - Outstanding at September 30, 2021 26,115 $ 76.76 0.51 Exercisable at September 30, 2021 26,115 $ 76.76 0.51 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued)

Related Party and former relate

Related Party and former related parties Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party and former related parties Transactions	Note 8 – Related Party and former related parties Transactions One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of September 30, 2021, the balance of the deferred compensation was $ 443,289 225,000 119,179 One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of September 30, 2021, the balance of his deferred compensation was $ 632,257 From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at September 30, 2021, was $ 6,529 13,405 13,405 As of September 30, 2021, notes payable remain outstanding to the former President of the Company, in the amount of $ 132,600 . As of September 30, 2021, accrued interests on these notes payable totaled $ 64,852 , and are included in accrued expenses on the condensed consolidated balance sheet. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued)

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 9 – Fair Value Measurements The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Schedule of Conversion Feature Using Black Scholes Option Pricing Model Nine months ended September 30, 2021 2020 Expected term 1 4 months 1 6 months Exercise price $ 0.012 0.030 $ 0.05 0.76 Expected volatility 177 206 157 249 Expected dividends None None Risk-free interest rate 0.06 0.13 0.03 1.54 Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2021: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2020 $ 4,202,597 Extinguishment (133,386 ) Debt conversion (585,857 ) Change in estimated fair value 2,962,795 Balance September 30, 2021 $ 6,446,149 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of September 30, 2021: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Prices in Active Significant Other Significant Identical Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total As of September 30, 2021 Derivative liability $ - $ - $ 6,446,149 $ 6,446,149 Total $ - $ - $ 6,446,149 $ 6,446,149

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies Legal Matters The Company is a defendant in a case brought by Auctus Fund, LLC seeking to enforce a variable rate convertible note dated in August 2019, which was in the original amount of $ 275,250 and claiming damages in excess of $ 500,000 , including other unspecified damages and attorney fees. The Company is vigorously defending the action and has filed an answer with counterclaims. While the matter is in its early stages and there are always uncertainties in litigation, management does not believe that the litigation will have a result significantly adverse to the Company. As of September 30, 2021, the balance of the variable rate convertible note is approximately $ 164,000 31,000 The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of September 30, 2021, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2021
Risks and Uncertainties [Abstract]
Concentrations	Note 11 – Concentrations Sales During the nine months ended September 30, 2021, we had two significant customers, which accounted for approximately 61 Supplier We also have a single source for our bioelectric medical devices, which account for 100 Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) Accounts Receivable At September 30, 2021, we had one customer which accounted for approximately 64

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Events Subsequent to September 30, 2021, an aggregate of 1,770,656 shares of restricted common stock were issued on the conversion of $ 35,153 of principal and $ 260 of accrued interest pursuant to fixed promissory notes. Subsequent to September 30, 2021, the Company executed two convertible notes for aggregate principal of $ 175,000 , carrying coupon of 15 %, with due date one year from issuance date, convertible six months from issuance date at a fixed conversion rate. Subsequent to September 30, 2021, the Company agreed to issue 1,225,000 commitment shares pursuant to securities purchase agreement executed in conjunction with the two convertible notes executed post September 30, 2021. The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The Management of the Company determined that there were no other reportable subsequent events to be disclosed besides those noted above.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2021, and 2020, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2021. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.
Liquidity and Going Concern	Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. As of September 30, 2021, the Company had cash of approximately $ 6,000 20.2 0.6 58.8 During the nine months ended September 30, 2021, the Company has raised approximately $ 0.6 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential, future, license agreements, has raised capital through the sale of its common stock, and the issuance of convertible promissory notes. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued)
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the nine months ended September 30, 2021, include stock options, warrants, and notes payable. The Company has 3,013,730 26,115 96,533 56,914 The components of basic and diluted earnings per share for the nine months ended September 30, 2021, and 2020 were as follows: Schedule of Earnings (Loss) Per Share 2021 2020 Nine months ended September 30, 2021 2020 Numerator: Net income (loss) attributable to common shareholders $ (5,501,224 ) $ 1,634,726 Effect of dilutive securities Convertible notes - (5,063,936 ) Net loss for diluted earnings per share $ (5,501,224 ) $ (3,429,210 ) Denominator: Weighted-average number of common shares outstanding during the period 55,303,026 9,621,530 Dilutive effect of convertible notes payable - 13,953,850 Common stock and common stock equivalents used for diluted earnings per share 55,303,026 23,575,380
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 as of September 30, 2021, and December 31, 2020. Account receivables are written off when all collection attempts have failed.
Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development 0 and $ 3,283 for the nine months ended September 30, 2021, and 2020, respectively, and are included in operating expenses in the condensed consolidated statements of operations. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued)
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Accounting Principles Not Yet Adopted In May 2021, the FASB issued ASU 2021-04 ASU 2021-04 Newly Adopted Accounting Principles In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s condensed consolidated results of operations, financial position, and cash flows. In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The objective of this standard update is to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. This ASU also attempts to improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard update is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2021, and the impact of adoption was not material to the Company’s financial position, results of operations and cash flows. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Earnings (Loss) Per Share	The components of basic and diluted earnings per share for the nine months ended September 30, 2021, and 2020 were as follows: Schedule of Earnings (Loss) Per Share 2021 2020 Nine months ended September 30, 2021 2020 Numerator: Net income (loss) attributable to common shareholders $ (5,501,224 ) $ 1,634,726 Effect of dilutive securities Convertible notes - (5,063,936 ) Net loss for diluted earnings per share $ (5,501,224 ) $ (3,429,210 ) Denominator: Weighted-average number of common shares outstanding during the period 55,303,026 9,621,530 Dilutive effect of convertible notes payable - 13,953,850 Common stock and common stock equivalents used for diluted earnings per share 55,303,026 23,575,380

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Source of Revenue	As of September 30, 2021, and 2020, the sources of revenue were as follows: Schedule of Source of Revenue Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Direct sales- Medical care providers, gross $ 7,790 $ 39,980 $ 72,789 $ 154,296 Total sources of revenue $ 7,790 $ 39,980 $ 72,789 $ 154,296

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2021, and December 31, 2020: Summary of Property, Plant and Equipment September 30, December 31, Autos $ 64,458 $ 64,458 Medical equipment 13,969 13,969 Other equipment 11,367 11,367 Property, Plant and Equipment, gross 89,794 89,794 Less accumulated depreciation 89,794 88,214 Property, Plant and Equipment, net $ - $ 1,580

Patents (Tables)

Patents (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	Schedule of Patents September 30, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,425,916 1,940,732 Patents, net $ 2,074,084 $ 2,559,268
Schedule of Estimated Future Amortization Expense	Schedule of Estimated Future Amortization Expense Twelve Months Ending September 30, Amount 2021 $ 646,910 2022 646,910 2023 646,910 2024 133,354 Total $ 2,074,084

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable	Schedule of Notes Payable September 30, December 31, 2020 Notes payable at beginning of period $ 6,835,196 $ 6,874,795 Notes payable issued 475,000 1,364,611 Liquidated damages - 452,095 Note modification - 25,190 Loan fees added to note payable - 120,389 Repayments of notes payable in cash (13,400 ) (22,000 ) Settlements on note payable (117,770 ) (697,253 ) Less amounts converted to stock (358,443 ) (1,282,631 ) Notes payable at end of period 6,820,583 6,835,196 Less debt discount (48,927 ) (201,157 ) $ 6,771,656 $ 6,634,039 Notes payable issued to a former related party $ 132,600 $ 143,000 Notes payable issued to non-related parties $ 6,639,056 $ 6,491,039
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Related party Non-related parties Total Past due $ 132,600 $ 3,370,533 $ 3,503,133 September 30, 2022 - 3,317,450 3,317,450 $ 132,600 $ 6,687,983 $ 6,820,583

Shareholders_ Deficit (Tables)

Shareholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Preferred Stock	Schedule of Preferred Stock Number of Number of Shares Outstanding Shares Authorized at September 30, 2021 Par Value Liquidation Value Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of September 30, 2021, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2021 3,014,080 $ 0.37 1.67 - Granted - $ - - - Cancelled (350 ) $ 47.00 - - Exercised - $ - - - Outstanding at September 30, 2021 3,013,730 $ 0.37 0.92 $ - Exercisable at September 30, 2021 1,263,730 $ 0.67 0.95 $ -
Schedule of Warrants Outstanding	A summary of the status of the warrants granted under these agreements at September 30, 2021, and changes during the nine months then ended is presented below: Schedule of Warrants Outstanding Outstanding Warrants Weighted Average Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2021 39,295 $ 200.72 0.93 Granted - $ - - Cancelled (13,180 ) $ 449.15 - Exercised - $ - Outstanding at September 30, 2021 26,115 $ 76.76 0.51 Exercisable at September 30, 2021 26,115 $ 76.76 0.51

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Conversion Feature Using Black Scholes Option Pricing Model	Schedule of Conversion Feature Using Black Scholes Option Pricing Model Nine months ended September 30, 2021 2020 Expected term 1 4 months 1 6 months Exercise price $ 0.012 0.030 $ 0.05 0.76 Expected volatility 177 206 157 249 Expected dividends None None Risk-free interest rate 0.06 0.13 0.03 1.54 Forfeitures None None
Schedule of Fair Value of Derivative Liability	Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2020 $ 4,202,597 Extinguishment (133,386 ) Debt conversion (585,857 ) Change in estimated fair value 2,962,795 Balance September 30, 2021 $ 6,446,149
Schedule of Liabilities Significant Unobservable Inputs	The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of September 30, 2021: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Prices in Active Significant Other Significant Identical Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total As of September 30, 2021 Derivative liability $ - $ - $ 6,446,149 $ 6,446,149 Total $ - $ - $ 6,446,149 $ 6,446,149

Schedule of Earnings (Loss) Per

Schedule of Earnings (Loss) Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income (loss) attributable to common shareholders			$ (5,501,224)	$ 1,634,726
Convertible notes				(5,063,936)
Net loss for diluted earnings per share			$ (5,501,224)	$ (3,429,210)
Weighted-average number of common shares outstanding during the period	66,291,292	16,137,373	55,303,026	9,621,530
Dilutive effect of convertible notes payable				13,953,850
Common stock and common stock equivalents used for diluted earnings per share	66,291,292	16,137,373	55,303,026	23,575,380

Summary of significant accoun_4

Summary of significant accounting policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 6,000
Working capital deficiency	20,200,000
Net cash used in operating activities	600,000
Accumulated deficit	58,839,746		$ 53,338,522
Proceeds from debt and equity financing	$ 600,000
Stock option issued	3,013,730	96,533
Warrant to purchase common stock	26,115	56,914
Accounts Receivable, Allowance for Credit Loss, Current	$ 0		$ 0
Research and Development Expense	$ 0	$ 3,283

Schedule of Source of Revenue (

Schedule of Source of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 7,790	$ 39,980	$ 72,789	$ 154,296
Direct Sales- Medical Care Providers [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 7,790	$ 39,980	$ 72,789	$ 154,296

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, gross	$ 89,794	$ 89,794
Less accumulated depreciation	89,794	88,214
Property, Plant and Equipment, net		1,580
Autos [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, gross	64,458	64,458
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, gross	13,969	13,969
Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, gross	$ 11,367	$ 11,367

Property, Plant and Equipment_2

Property, Plant and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,580	$ 3,432

Schedule of Patents (Details)

Schedule of Patents (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	2,425,916	1,940,732
Patents, net	$ 2,074,084	$ 2,559,268

Schedule of Estimated Future Am

Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 646,910
2022	646,910
2023	646,910
2024	133,354
Patents, net	$ 2,074,084	$ 2,559,268

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 31, 2017	Sep. 30, 2021	Sep. 30, 2020
Amortization expense		$ 485,184	$ 485,184
Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expiration period	2024

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes payable at beginning of period	$ 6,835,196	$ 6,874,795
Notes payable issued	475,000	1,364,611
Liquidated damages		452,095
Note modification		25,190
Loan fees added to note payable		120,389
Repayments of notes payable in cash	(13,400)	(22,000)
Settlements on note payable	(117,770)	(697,253)
Less amounts converted to stock	(358,443)	(1,282,631)
Notes payable at end of period	6,820,583	6,835,196
Less debt discount	(48,927)	(201,157)
Note payable, net	6,771,656	6,634,039
Notes payable issued to a former related party	132,600	143,000
Notes payable issued to non-related parties	$ 6,639,056	$ 6,491,039

Schedule of Maturity Dates of N

Schedule of Maturity Dates of Notes Payable (Details)	Sep. 30, 2021USD ($)
Defined Benefit Plan Disclosure [Line Items]
Past due	$ 3,503,133
June 30, 2022	3,317,450
Total	6,820,583
Former Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	132,600
June 30, 2022
Total	132,600
Non-Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	3,370,533
June 30, 2022	3,317,450
Total	$ 6,687,983

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Short-term Debt [Line Items]
Promissory notes	$ 6,820,583		$ 6,835,196	$ 6,874,795
Proceeds from Notes Payable	$ 475,000	$ 401,424
Debt instrument, interest rate	15.00%
Gain on debt extinguishment	$ 28,536	$ (564,385)
Notes Payable, Related Parties, Current	132,600		$ 143,000
Gain (Loss) on Derivative Instruments [Member]
Short-term Debt [Line Items]
Gain on debt extinguishment	58,407
Two Promissory Notes [Member]
Short-term Debt [Line Items]
Promissory notes	475,000
Proceeds from Notes Payable	$ 475,000
Debt instrument description	original terms of twelve months and interest rates of 15%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features.
One Promissory Notes [Member]
Short-term Debt [Line Items]
Gain on debt extinguishment	$ 128,000
Number of shares issued for debt	1,515,152
Percentage of debt provision	15.00%
Promissory Notes [Member]
Short-term Debt [Line Items]
Repayment of debt	$ 3,000
Debt conversion, value	358,443
Accrued interest	$ 99,892
Debt conversion, stock issued	25,690,651
Convertible Debentures One [Member]
Short-term Debt [Line Items]
Convertible Debt	$ 4,770,926
Convertible Debentures One [Member] | Past Maturity [Member]
Short-term Debt [Line Items]
Convertible Debt	2,660,476
Notes Payable [Member] | Related Party [Member]
Short-term Debt [Line Items]
Repayment of debt	10,400
Notes Payable, Related Parties, Current	$ 132,600
Notes Payable [Member] | Related Party [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate	10.00%
Notes Payable [Member] | Related Party [Member] | Maximum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate	12.00%
Notes Payable One [Member]
Short-term Debt [Line Items]
Promissory notes	$ 1,292,154
Notes Payable One [Member] | Past Maturity [Member]
Short-term Debt [Line Items]
Promissory notes	$ 85,154

Schedule of Preferred Stock (De

Schedule of Preferred Stock (Details)	Sep. 30, 2021USD ($)$ / sharesshares
Series AA [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	1,000,000
Number of Shares Outstanding	25,000
Par Value | $ / shares	$ 0.0010
Liquidation Value | $
Preferred Series B [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	50,000
Number of Shares Outstanding	600
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 100
Preferred Series C [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	8,000
Number of Shares Outstanding	738
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 1,000
Preferred Series D [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	20,000
Number of Shares Outstanding	305
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 1,000
Undesignated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	3,922,000
Number of Shares Outstanding
Par Value | $ / shares
Liquidation Value | $

Schedule of Stock Options Outst

Schedule of Stock Options Outstanding (Details) - USD ($)	Jun. 11, 2020	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option Outstanding, Granted	74,668,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option Outstanding, Beginning Balance		3,014,080
Weighted Average Exercise Price, Beginning Balance		$ 0.37
Weighted Average Remaining Contractual Term (years), Outstanding Beginning		1 year 8 months 1 day
Aggregated Intrinsic Value, Outstanding Beginning Balance
Stock Option Outstanding, Granted
Weighted Average Exercise Price, Granted
Weighted Average Remaining Contractual Term (years), Granted
Aggregated Intrinsic Value, Outstanding, Granted
Stock Option Outstanding, Cancelled		(350)
Weighted Average Exercise Price, Cancelled		$ 47
Weighted Average Remaining Contractual Term (years), Cancelled
Aggregated Intrinsic Value, Outstanding, Cancelled
Stock Option Outstanding, Exercised
Weighted Average Exercise Price, Exercised
Weighted Average Remaining Contractual Term (years), Exercised
Aggregated Intrinsic Value, Outstanding, Exercised
Stock Option Outstanding, Ending Balance		3,013,730
Weighted Average Exercise Price, Ending Balance		$ 0.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		11 months 1 day
Aggregated Intrinsic Value, Outstanding Ending
Stock Option Outstanding, Exercisable Ending Balance		1,263,730
Weighted Average Exercise Price, Exercisable Ending Balance		$ 0.67
Weighted Average Remaining Contractual Term (years), Exercisable		11 months 12 days
Aggregated Intrinsic Value, Exercisable Ending

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Outstanding, Beginning Balance | shares	39,295
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 200.72
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	11 months 4 days
Shares, Granted | shares
Weighted-Average Exercise Price, Granted | $ / shares
Shares, Cancelled | shares	(13,180)
Weighted average Exercise price, Cancelled | $ / shares	$ 449.15
Shares, Exercised | shares
Weighted-Average Exercise Price, Exercised | $ / shares
Shares Outstanding, Ending Balance | shares	26,115
Weighted-Average Exercise Price, Outstanding Ending Balance | $ / shares	$ 76.76
Weighted Average Remaining Contractual Term (years), Outstanding Ending	6 months 3 days
Shares Exercisable, Ending Balance | shares	26,115
Weighted-Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 76.76
Weighted Average Remaining Contractual Term (years), Exercisable Ending	6 months 3 days

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)	Aug. 05, 2021	Jun. 11, 2020	May 18, 2020	Jan. 29, 2020	Dec. 22, 2017	Feb. 07, 2017	Feb. 22, 2013	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Nov. 11, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value								$ 20,491		$ 126,000	$ 100,000
Issuance of common stock														2,500,000
Common stock price per share								$ 0.0001						$ 0.0001		$ 0.0001
Shares issued for conversion of notes payable and accrued interest								$ 126,460	$ 116,546	$ 833,198	70,410	$ 475,962	$ 2,545,714
Common stock issued for services, shares															385,000
Common stock issued for services											36,000	3,500			$ 39,500
Gain on debt extinguishment														$ 28,536	(564,385)
Stock issued value conversion of series C induced to convert
Share-based compensation expenses														61,000
Unrecognized compensation expense														$ 137,000
Stock option to officers		74,668,000
Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for conversion of notes payable and accrued interest, shares	1,770,656
Gain on debt extinguishment															$ 55,000
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings															500,000
Stock issued value conversion of series C induced to convert															$ 55,000
One Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value															$ 58,855
Issuance of common stock															409,000
Convertible note principal amount											283,000				$ 283,000
Convertible debt											$ 525,000				525,000
Gain on debt extinguishment															151,496
Promissory Notes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock														4,333,668
Shares issued for conversion of notes payable and accrued interest, shares														25,690,651
Shares issued for conversion of notes payable and accrued interest														$ 458,335
Settlement of Debt [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value														$ 142,424
Issuance of common stock														4,020,986
Share Issuance for Total Consideration [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value														$ 126,000	$ 100,000
Issuance of common stock														7,000,000	1,234,568
Conversion of Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value														$ 33,333	$ 1,400,934
Issuance of common stock														1,111,111	2,754,822
Conversion of Notes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for conversion of notes payable and accrued interest, shares															8,501,004
Shares issued for conversion of notes payable and accrued interest															$ 1,381,650
Conversion of Series C Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value															$ 8,152
Issuance of common stock															58,428
Cavalry Fund I LP [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value															$ 97,918
Issuance of common stock															771,926
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase obligation			$ 10,000,000
Issuance of common stock			300,000
Commitment shares to be issued pro-rata			$ 3,000,000
Commitment share description			The ELPA provides that at any time after the effective date of the registration statement and provided the closing sale price of the common shares on the OTCQB is not below $0.01, from time to time on any business day selected by the Company (the “Purchase Date”), the Company shall have the right, but not the obligation, to direct the investor to buy up to 300,000 shares of the common stock (the “regular purchase amount”) at a purchase price equal to the lower of: (i) the lowest applicable sales price on the date of the put and (ii) 85% of the arithmetic average of the 3 lowest closing prices for the common stock during the 10 consecutive trading days ending on the trading day immediately preceding such put date. The regular purchase amount may be increased as follows: to up to 400,000 shares of common stock if the closing price of the common shares is not below $0.25 per share and up to 500,000 shares if the closing price is not below $0.40 per share.
Proceeds of puts to the payment			50.00%
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock price per share			$ 0.01
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock			400,000
Common stock price per share			$ 0.25
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock			500,000
Common stock price per share			$ 0.40
Former Related Party [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value														$ 84,697
Issuance of common stock														2,505,834
Series AA Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized							1,000,000
Preferred stock, par value							$ 0.001
Preferred stock voting rights							Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.
Preferred stock, outstanding								25,000						25,000
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized						50,000
Preferred stock, outstanding								600						600
Stated value dividend						75.00%
Warrants term						three-year
Share exercise price						150.00%
Liquidation value of preferred stock, per share						$ 100
Series C Convertible Redeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized					8,000
Liquidation value of preferred stock, per share								$ 1,000						$ 1,000
Preferred stock, dividend per share					$ 20
Shares issued, price per share					$ 1,000
Change in rights due to amendment and restated certificate, description				the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock.
Convertible preferred stock, shares outstanding								738						738
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of stock, shares converted														1,111,111	2,754,822
Series D Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized								20,000						20,000		20,000	20,000
Preferred stock, par value								$ 0.0001						$ 0.0001		$ 0.0001
Preferred stock, outstanding								305						305		305
Liquidation value of preferred stock, per share								$ 1,000						$ 1,000
Preferred Stock Designated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized								5,000,000						5,000,000
Series C Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of stock, shares converted														25	1,051
Commitment Shares [Member] | Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value			$ 500,000
Commitment Shares [Member] | Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock			3,859,630
Commitment Shares [Member] | Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock			385,963
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock, value															$ 165,000
Issuance of common stock															1,500,000
Stock issued for reverse stock splits															34,690

Related Party and former rela_2

Related Party and former related parties Transactions (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Repayment of debt	$ 10,400	$ 19,000
Notes Payable, Related Parties, Current	132,600		$ 143,000
Interest Payable, Current	2,334,302		$ 1,904,136
Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation	443,289
Accrual of deferred compensation	225,000
Cash repayments of deferred compensation	119,179
Advance from officer	13,405
Repayment of debt	13,405
One Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation	632,257
Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Due to officer	6,529
Former President [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Notes Payable, Related Parties, Current	132,600
Interest Payable, Current	$ 64,852

Schedule of Conversion Feature

Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details)	9 Months Ended
	Sep. 30, 2021$ / shares	Sep. 30, 2020$ / shares
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	1 month	1 month
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	4 months	6 months
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, exercise price	$ 0.012	$ 0.05
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, exercise price	$ 0.030	$ 0.76
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	1.77	1.57
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	2.06	2.49
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0006	0.0003
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0013	0.0154
Forfeitures [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0

Schedule of Fair Value of Deriv

Schedule of Fair Value of Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member]	9 Months Ended
	Sep. 30, 2021USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, beginning	$ 4,202,597
Extinguishment	(133,386)
Debt conversion	(585,857)
Change in estimated fair value	2,962,795
Derivative Liability, ending	$ 6,446,149

Schedule of Liabilities Signifi

Schedule of Liabilities Significant Unobservable Inputs (Details)	Sep. 30, 2021USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 6,446,149
Total	6,446,149
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	6,446,149
Total	$ 6,446,149

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended
	Aug. 31, 2019	Sep. 30, 2021	Dec. 31, 2020
Loss Contingencies [Line Items]
Accrued interest		$ 2,334,302	$ 1,904,136
Convertible Debt [Member] | Variable Rate [Member]
Loss Contingencies [Line Items]
Debt covertible note		164,000
Accrued interest		$ 31,000
Auctus Fund, LLC [Member] | Other Unspecified Damages And Attorney Fees [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 500,000
Auctus Fund, LLC [Member] | Note [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 275,250

Concentrations (Details Narrati

Concentrations (Details Narrative)	9 Months Ended
	Sep. 30, 2021
Revenue Benchmark [Member] | Supplier Concentration Risk [Member] | Two Significant Customers [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	61.00%
Revenue Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	64.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Aug. 05, 2021	Sep. 30, 2021	Aug. 01, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		15.00%
Securities Purchased under Agreements to Resell		$ 1,225,000
Convertible Notes Two Payable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Instrument, Face Amount		$ 175,000
Debt Instrument, Interest Rate, Stated Percentage			15.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,770,656
Debt Conversion, Original Debt, Amount	$ 35,153
Interest Payable	$ 260